Abstract
AB002. Anlotinib as salvage treatment for patients with relapsed and refractory thymic epithelial tumors
Chang-Lu Wang1, Yi-Zhuo Zhao2, Qin Zhang1, Wan-Qin Zeng1, Tian-Ying Jia1, Lei Zhu3, Wen-Tao Fang4, Xiao-Long Fu1
1Department of Radiation Oncology, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China;
2Department of Respiratory, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China;
3Department of Pathology, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China;
4Department of Thoracic Surgery, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China
Correspondence to: Chang-Lu Wang. Department of Radiation Oncology, Shanghai Chest Hospital, No. 241, West Huaihai Road, Shanghai 200030, China. Email: luise2w@msn.com.
Background: Optimal pharmaceutical regimen for advanced thymic epithelial tumors (TETs) remains controversial when first-line chemotherapy fails. This retrospective study aims to evaluate the efficacy and safety of anlotinib treatment for patients with relapsed and refractory TETs.
Methods: Patients with progression disease after failure of platinum-based chemotherapy were enrolled in this study. Anlotinib was orally taken once a day at an initial dose of 12 mg (10 mg when body weight <60 kg). The cycle was repeated every 3 weeks (2 weeks of treatment followed by 1 week rest). There are 3 dose levels (12, 10 and 8 mg), and dose may be reduced to a lower level when grade 3 toxicity occurred. Objective response rate (ORR) and progression-free survival (PFS) were recorded as primary end points, and they were analyzed separately in thymoma (THY) and thymic carcinoma (TC) cohorts. Meanwhile, toxicities were assessed according to CTCAE (version 5.0).
Results: There were 50 patients enrolled in this study from October 2018 to June 2021 at a median age of 50 (range, 23–79) years old. Patients with THY and TC were 33 (66%) and 17 (34%) respectively. The ORR in THY and TC patients were 33% (11/33) and 41% (7/17), respectively. The median PFS (mPFS) were 7 (95% CI: 5.9–10.2) months in THY patients and 6 (95% CI: 4.6–9.3) months in TC group. Eleven patients experienced dose reduction due to toxicities, among whom, 8 patients discontinued treatment even after dose reduction. Six patients with THY showed myasthenia gravis (MG) deterioration during treatment, and 2 of them died of MG crisis.
Conclusions: Anlotinib is active in patients with advanced TETs refractory to routine chemotherapy. Prescription of Anlotinib to patients with MG should be made cautiously.
Keywords: Thymic epithelial tumor; anlotinib; molecular
doi: 10.21037/med-22-ab002
Acknowledgments
Funding: None.
Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://med.amegroups.com/article/view/10.21037/med-22-ab002/coif). The authors have no conflicts of interest to declare.
Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.
Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.
doi: 10.21037/med-22-ab002
Cite this abstract as: Wang CL, Zhao YZ, Zhang Q, Zeng WQ, Jia TY, Zhu L, Fang WT, Fu XL. Anlotinib as salvage treatment for patients with relapsed and refractory thymic epithelial tumors. Mediastinum 2022;6:AB002.
